1 / 30

ESSENTIALS OF GLYCOBIOLOGY LECTURE 14 GLYCOCONJUGATE DEGRADATION and LYSOSOMAL STORAGE DISEASES Hud Freeze

ESSENTIALS OF GLYCOBIOLOGY LECTURE 14 GLYCOCONJUGATE DEGRADATION and LYSOSOMAL STORAGE DISEASES Hud Freeze. USUAL TURNOVER Most glycans are extracellular or on cell surface Membrane recycling (50%/hr) Receptor and non-receptor mediated endocytosis. To Endosome Lysosome.

elisha
Download Presentation

ESSENTIALS OF GLYCOBIOLOGY LECTURE 14 GLYCOCONJUGATE DEGRADATION and LYSOSOMAL STORAGE DISEASES Hud Freeze

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ESSENTIALS OF GLYCOBIOLOGY LECTURE 14 GLYCOCONJUGATE DEGRADATION and LYSOSOMAL STORAGE DISEASES Hud Freeze

  2. USUAL TURNOVER • Most glycans are extracellular or on cell surface • Membrane recycling (50%/hr) • Receptor and non-receptor • mediated endocytosis To Endosome Lysosome Lysosomal exoglycosidases degrade glycans at low pH Specific lysosomal transporters carry neutral hexose, acetylatedaminohexose (GlcNAc, GalNAc), and Anionic sugars (GlcA, Sia) to the cytoplasm.

  3. SUGAR CHAIN DEGRADATION ENZYMES Most Are: Lysosome/Endosome Low pH optimum, Sugar/anomeric specificity Exo-glycosidases Targeted to lysosome through P-lectins and Man-6-P But Some Are: Non-lysosomal Active near neutral pH Endoglycosidases Targeted as membrane bound molecules Not in the lysosome

  4. Special Features for Degradation of Different Glycoconjugates TYPEFEATURE Glycoproteins N-linked ER/Golgi/Cytoplasm/ Lysosome O-linked Unexpected Products Proteoglycans Endoglycosidases Unique ORDER Non-glycohydrolase enzymes Glycosphingolipids Assisting proteins

  5. Special Problems for N-Linked Sugar Chains • N-glycosylation occurs in ER-Topology for lysosomal degradation is wrong • ~50% of ER proteins misfold and are degraded - what happens to the sugar chain? To glycopeptides? • Protein synthetic rate and glycosylation rate must be coordinated • Competition for lectin-based chaperones

  6. lots of Man( ) Released What happens to the released mannose?

  7. OLIGOSACCHARIDE HOUSE-KEEPING CENTRAL

  8. MANNOSE METABOLISM IN CELLS AND MORE Mannose in plasma comes from Oligosaccharide turnover in cells Cells also produce mannose From glucose Glc Glc-6-P Fru-6-P Man-6-P Golgi cytosol Lysosome Glycans ER

  9. Lysosomal degradation of N-linked oligosaccharides

  10. Lysosomal degradation of N-linked oligosaccharides

  11. Enzymatic defects are usually found by accumulation of Partially degraded oligosaccharides in urine

  12. O-LINKED OLIGOSACCHARIDE DEGRADATION Same enzymes used for N-linked oligosaccharide degradation a-GalNAc’ase deficiency--produce GalNAc terminated Oligosaccharides? Excretion of GalNAc-a-Ser/Thr? No!! Why Not? The oligosaccharides are larger size! How to explain this? a Ser/Thr a Ser/Thr

  13. ** Partially degraded polysaccharides accumulate in tissues and urine. Structural analysis of glycans used to work out pathway

  14. Hyaluronan degradation

  15. HEPARAN SULFATE DEGRADATION

  16. HEPARAN SULFATE DEGRADATION

  17. CHONDROITIN SULFATE DEGRADATION

  18. DISEASESOF GLYCOLIPID DEGRADATION ** **

  19. GSL Degradation Needs Assistants

  20. LIFE CYCLE OF GM2 ACTIVATOR PROTEIN

  21. Model for the degradation of membrane-bound GlcCer by glucocerebrosidase and SAP-C and Cer by acid ceramidase and SAP-D, respectively. Besides the interaction of lysosomal enzyme and activator protein, the model emphasizes binding of activator protein and lysosomal enzymes to the vesicular surface containing BMP.

  22. What determines differences in patient outcome?

  23. Tissue Destruction Cell loss Phagocytosis Exosystosis Synthesis catabolism Cell proliferation Cell turnover Uptake TREATMENT FOR LYSOSOMAL STAORAGE DISEASES SUBSTRATE DEPLETION THERAPY ENZYME REPLACMENT THERAPY S I = SE SUBSTRATE ACCUMULATION

  24. ENZYME REPLACEMENT THERAPY • WHAT PROBLEMS WOULD YOU ENCOUNTER ? • Get it to the right cells? • Is it stable in the cells? • Does it need co-factors? • Can it degrade already accumulated materials? • Does it cross the blood brain barrier? • Does it generate antibodies? SUBSTRATE DEPLETION THERAPY Potential advantages Small molecules cross the blood-brain barrier Targeting initial step reduces all intermediates

  25. ENZYME REPLACEMENT THERAPY FIRST ATTEMPTED IN ~1980 Gaucher Disease Glucosyl Ceramide deficiency. Modified the N-linked glycans targets enzyme to the liver macrophage through a Man/GlcNAc receptor Used in >3000 patients as productCerezyme (Genzyme) Other enzymes used to treat Fabry (a-Galactosidase), MPSI a-L-iduronidase SUBSTRATE DEPLETION THERAPY First Clinical trials using N-Butyldeoxynojirimycin, (miglustat 'Zavesca') on Gaucher patients were successful Results for animal models for other disorders appear promising

  26. Scorecard for Enzyme Replacement Therapy

  27. QUESTIONS ??

  28. REMEMBER THAT • Different glycans have unique degradation pathways • Mutations in degradative enzymes lead to rare diseases that are cell/organ specific in their pahology • Limiting glycan synthesis or replacing deficient enzymes in genetic disorders may reduce some pathology

More Related